Results 231 to 240 of about 4,376,584 (354)

Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Real‐world initial treatment strategies in systemic sclerosis–associated pulmonary arterial hypertension (SSc‐PAH) remain incompletely described. We aimed to characterize these strategies across hemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analyzed treatment‐naive patients with SSc‐PAH from the European
Hilde Jenssen Bjørkekjær   +63 more
wiley   +1 more source

Korean Clinical Practice Guidelines for Interstitial Lung Disease: Part 2. Idiopathic Pulmonary Fibrosis. [PDF]

open access: yesTuberc Respir Dis (Seoul)
Choi HS   +8 more
europepmc   +1 more source

Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=
Jaime Marty   +21 more
wiley   +1 more source

Lymphangioleiomyomatosis diagnosed by transbronchial lung cryobiopsy in a patient with hemoptysis: a case report. [PDF]

open access: yesRespir Res Clin Pract
Bridi GDP   +7 more
europepmc   +1 more source

Unclassifiable interstitial lung diseases: Clinical characteristics and survival

open access: yesRespirology (Carlton South. Print), 2017
C. Hyldgaard   +3 more
semanticscholar   +1 more source

Acute exacerbation in fibrotic interstitial lung disease: an international working group report. [PDF]

open access: yesAm J Respir Crit Care Med
Khor YH   +40 more
europepmc   +1 more source

Safety of proton pump inhibitors in children: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To systematically evaluate the safety of proton pump inhibitor (PPI) therapy in children aged 0–12 years, with a focus on treatment‐emergent adverse events across different study designs and age groups. Method The systematic review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA ...
Ahmad Raza Sachel   +2 more
wiley   +1 more source

Health-related quality of life assessment using KBILD in fibrotic interstitial lung diseases receiving antifibrotic therapy: a prospective longitudinal study. [PDF]

open access: yesERJ Open Res
Suzuki Y   +27 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy